Metastatic Merkel Cell Carcinoma: Insights on the Clinical Application of Immune Checkpoint Inhibitors

This multifaceted program, which includes a CME-certified text module, interactive toxicity management algorithm tool, summary resource guide, and expert commentaries, equips clinicians with evidence-based insights on how to incorporate immune checkpoint inhibitors into clinical management of patients with metastatic Merkel cell carcinoma.
Shailender Bhatia, MD
Sandra P. D'Angelo, MD
Howard L. Kaufman, MD
Evan J. Lipson, MD
Paul Nghiem, MD
Jeffrey S. Weber, MD, PhD

ClinicalThought

In this commentary, Sandra P. D’Angelo, MD, highlights the practice-changing use of immune checkpoint inhibitor therapy for the treatment of patients with metastatic Merkel cell carcinoma.

Sandra P. D'Angelo, MD Released: November 30, 2016

In this commentary Shailender Bhatia, MD, shares his perspective on the unprecedented efficacy of immunotherapy in treating a patient with bulky metastatic MCC.

Shailender Bhatia, MD Released: February 27, 2017

In this commentary, Howard L. Kaufman, MD, highlights practice-changing clinical trial results on avelumab, the first FDA-approved treatment for metastatic Merkel cell carcinoma.

Howard L. Kaufman, MD Released: May 19, 2017

With avelumab now approved for MCC, what treatment options are available to patients not responding to checkpoint inhibitors? Read my thoughts on a promising new approach.

Paul Nghiem, MD Released: August 9, 2017

Module

Experts review current data on immunotherapies and provide their perspectives on optimal management of patients with metastatic Merkel cell carcinoma.

Shailender Bhatia, MD Sandra P. D'Angelo, MD Evan J. Lipson, MD Paul Nghiem, MD Physicians: maximum of 2.25 AMA PRA Category 1 Credits Released: February 22, 2017 Expiration: February 21, 2018

In this downloadable slideset, distinguished faculty members Paul Nghiem, MD; Shailender Bhatia; MD, Sandra P. D’Angelo, MD; and Evan J. Lipson, MD, review key data and current practice changes in the treatment of advanced MCC. For additional in-depth analysis of the slideset, please review the accompanying CME-certified text module.

Released: February 22, 2017

Summary Resource

In this downloadable resource, expert faculty Paul Nghiem, MD reviews the rationale for and key data supporting the use of immune checkpoint inhibitors in the treatment of MCC. For additional in-depth analysis, please review the accompanying CME-certified text module, downloadable slides, and ClinicalThought commentaries, as well as our interactive algorithm tool for expert guidance with managing immune-related adverse events.

Released: March 6, 2017

Interactive Decision Support Tool

Use this newly updated Interactive Algorithm Tool to receive expert guidance from Jeffrey S. Weber, MD, PhD, on how to manage immune-related adverse events for your patients receiving immune checkpoint inhibitors, based on the organ system affected and the severity of the event.

Jeffrey S. Weber, MD, PhD Released: May 9, 2017
Jointly provided by the Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC

Annenberg Center for Health Sciences at Eisenhower
39000 Bob Hope Dr
Dinah Shore Bldg.
Rancho Mirage, CA 92270

Alma Perez, Accreditation Specialist
(760) 773-4506
(760) 773-4550 (Fax)
ce@annenberg.net
http://www.annenberg.net/

This activity is supported by an educational grant from
Pfizer Inc.
Merck KGaA

Welcome to the CCO site.

You are accessing CCO's educational content today as a Guest user.

If you would like to continue with free, full access to the CCO Web sites, including free CME/CE credits, please click the button below.

Continue

More info

CCO’s educational programs are available completely free of charge on the ClinicalOptions.com, inPractice.com, and inPracticeAfrica.com Web sites. Certain features and functions are restricted for Guest users. By consenting to become a full member, you are eligible to receive CME/CE credit or participation certificates from certified activities, to register for CCO’s free live meetings and webinars, and to receive CCO’s email newsletters alerting you to new content. You can unsubscribe from our emails at any time. CCO strictly protects the privacy of our members, according to our privacy policy.

A confirmation email will be sent to . Not You?